A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine if armodafinil is safe and effective in
treating fatigue in patients with malignant gliomas undergoing treatment with radiotherapy
plus temodar. Armodafinil is a wakefulness-promoting agent that has been FDA approved for the
treatment of excessive daytime sleepiness for a variety of disorders. Armodafinil may also
help to reduce radiation-induced fatigue in brain tumor patients.
Phase:
Phase 2
Details
Lead Sponsor:
Eudocia Quant Lee, MD
Collaborators:
Beth Israel Deaconess Medical Center Cephalon Dartmouth-Hitchcock Medical Center University of California, San Diego